US President Trump announced agreements with nine major pharmaceutical companies to lower prescription drug prices in the US, aligning them with those in other wealthy nations. These deals will impact Medicaid pricing and introduce “most-favoured-nation” pricing for new drugs across all markets. Companies also committed to a direct-to-consumer platform and offered discounts.